Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine and MIT for Cannabis Dependence
NCT00167297Phase 2Completed
- Sponsor
- National Institute on Drug Abuse
- Start
- Nov 2004
- Primary completion
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atomoxetine in cannabis use disorder (CUD), sponsored by National Institute on Drug Abuse. Primary endpoint: Marijuana use measured by weekly urine drug screens at 8 weeks. Started Nov 2004; status: completed.
02
Drugs
atomoxetine
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT00167297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00167297.